These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 7855789)
1. Thrombin-Hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Gallistl S; Muntean W Thromb Haemost; 1994 Sep; 72(3):387-92. PubMed ID: 7855789 [TBL] [Abstract][Full Text] [Related]
2. In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. Kaiser B; Fareed J; Walenga JM; Hoppensteadt D; Markwardt F Thromb Res; 1991 Dec; 64(5):589-96. PubMed ID: 1808763 [TBL] [Abstract][Full Text] [Related]
3. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Gallistl S; Muntean W; Leis HJ Thromb Haemost; 1995 Oct; 74(4):1163-8. PubMed ID: 8560429 [TBL] [Abstract][Full Text] [Related]
4. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Zoldhelyi P; Bichler J; Owen WG; Grill DE; Fuster V; Mruk JS; Chesebro JH Circulation; 1994 Dec; 90(6):2671-8. PubMed ID: 7994807 [TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120 [TBL] [Abstract][Full Text] [Related]
6. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency. Herren T; Straub PW; Haeberli A Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646 [TBL] [Abstract][Full Text] [Related]
7. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594 [TBL] [Abstract][Full Text] [Related]
8. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368 [TBL] [Abstract][Full Text] [Related]
9. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Kaiser B; Fareed J; Hoppensteadt D; Birdsong B; Walenga JM; Markwardt F Thromb Res; 1992 Jan; 65(2):157-64. PubMed ID: 1579892 [TBL] [Abstract][Full Text] [Related]
10. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778 [TBL] [Abstract][Full Text] [Related]
11. Laboratory assays for the evaluation of recombinant hirudin. Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197 [TBL] [Abstract][Full Text] [Related]
12. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786 [TBL] [Abstract][Full Text] [Related]
13. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation. Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547 [TBL] [Abstract][Full Text] [Related]
15. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Elgue G; Blombäck M; Olsson P; Riesenfeld J Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137 [TBL] [Abstract][Full Text] [Related]
16. Thrombin-hirudin complex stability: a comparison with the thrombin-antithrombin III complex. Römisch J; Pâques EP Blood Coagul Fibrinolysis; 1991 Oct; 2(5):643-6. PubMed ID: 1782334 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789 [TBL] [Abstract][Full Text] [Related]
18. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548 [TBL] [Abstract][Full Text] [Related]
19. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
20. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation]. Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]